Trulieve Cannabis Corp.

Trulieve Cannabis Corp. Earnings Recaps

TRLV 2 recaps
Next earnings: March 4, 2027 (estimated) · full calendar
Q3 2026 Nov 7, 2026

Shares fell 6.0% after the earnings release, despite revenue exceeding management’s guidance. The transcript points to limited underlying growth—revenue rose 4% year over year and sequentially on a medical-only basis—and a slight sequential decline in average basket size as possible sources of investor disappointment; it does not disclose a specific guidance cut or margin deterioration.

Key takeaways
  • Third-quarter revenue was $230 million, up 4% year over year and sequentially versus medical-only results in prior periods.
  • Gross margin was 64%, up 1% versus medical-only results a year earlier; adjusted EBITDA was $89 million, a 39% margin.
  • Operating cash flow was $74 million, and quarter-end cash was $327 million. After quarter-end, Trulieve repaid a $65 million mortgage, which management said would reduce annual interest expense.
  • Retail revenue grew 2% sequentially. Traffic rose 3% and units sold increased 2%, while average basket size declined slightly.
  • Georgia traffic and units increased sevenfold with market expansion and new product types; Pennsylvania also contributed to retail revenue growth.
Q2 2026 Aug 10, 2026

Shares fell 2.8% as investors appeared cautious about the uncertain impact of the recent business deconsolidation and mixed signals on growth, despite stable revenue and margin performance in the core medical-only operations.

Key takeaways
  • Reported Q2 revenue of $271 million included combined results until June 3rd, then only the medical-only business after the deconsolidation from Harvest’s mixed-use operations.
  • The removal of the 280E tax provided a near-term boost to net income and cash flow, but the company did not highlight sustained margin expansion post-deconsolidation.
  • Management detailed significant near-term growth opportunities in Georgia, Texas (pending license conversion), and customer acquisition from the intoxicating hemp market, but these remain contingent and developmental.
  • The company completed DEA registration and inspections for its medical dispensaries, a regulatory milestone tied to future federal rescheduling, yet timing of approvals remains pending.
  • Market reaction suggests investors remain guarded given the complexity of the restructuring and lack of clear forward guidance on mixed-use segment contribution and overall growth trajectory.